Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia 4 Jan Written by Alexandra Collingbourne Alexandra Collingbourne Previous Previous Qureight founder: Pitching to investors is energising once you take the plunge Next Next Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing
Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia 4 Jan Written by Alexandra Collingbourne Alexandra Collingbourne